Wockhardt shares on December 1 jumped 19% after the US FDA accepted the company’s New Drug Application for Zaynich, its first-in-class antibiotic. But the rally cooled over the next two days as investors booked profits, leading to back-to-back 5% drops.
AU Small Finance Bank Q2 profit jumps 53% to Rs 858 crore
AU’s gross non-performing assets ratio fell 42 basis points (bps) to 1.99% at the end of September. This helped in 25% lower provision at Rs